ContributorsPublishersAdvertisers

HRQOL Decreased During and Immediately After CAR T-Cell Therapy for DLBCL

ajmc.com
 2021-11-16

Cover picture for the articlePrior to chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), patients experienced a decrease in health-related quality of life (HRQOL), which was further impaired during and immediately after CAR T therapy. Patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) have often exhausted multiple...

www.ajmc.com

Comments / 0

Comments / 0